Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 48 articles: HTML format

Single Articles

September 2022
1. WU J, Tan X
   The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
   Int J Cancer. 2022;151:888-896.
   PubMed     Abstract available
   
   
   August 2022
2. JAMES ND, Clarke NW, Cook A, Ali A, et al
   Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
   Int J Cancer. 2022;151:422-434.
   PubMed     Abstract available
   
   
   July 2022
3. CARM KT, Johannessen B, Bogaard M, Bakken AC, et al
   Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.
   Int J Cancer. 2022 Jul 26. doi: 10.1002/ijc.34226.
   PubMed     Abstract available
   
   
   
4. OSTMAN JR, Pinto RC, Ebbels TM, Thysell E, et al
   Identification of pre-diagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry-based metabolomics: A case-control study nested in the Northern Sweden Health and Disease Study.
   Int J Cancer. 2022 Jul 22. doi: 10.1002/ijc.34223.
   PubMed     Abstract available
   
   
   
5. GEDEBORG R, Loeb S, Styrke J, Kiiski-Berggren R, et al
   Susceptibility to SARS-Cov-2 Infection and Risk for Severe COVID-19 in Patients with Prostate Cancer on Androgen Deprivation Therapy.
   Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34204.
   PubMed     Abstract available
   
   
   June 2022
6. CSIZMARIK A, Keresztes D, Nagy N, Bracht T, et al
   Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
   Int J Cancer. 2022 Jun 11. doi: 10.1002/ijc.34159.
   PubMed     Abstract available
   
   
   May 2022
7. WATTS EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, et al
   Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia.
   Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34116.
   PubMed     Abstract available
   
   
   April 2022
8. FORSTER RB, Engeland A, Kvale R, Hjellvik V, et al
   Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in non-metastatic prostate cancer.
   Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34058.
   PubMed     Abstract available
   
   
   
9. MATSUSHITA M, Fujita K, Hatano K, Hayashi T, et al
   High-fat diet promotes prostate cancer growth through histamine signaling.
   Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34028.
   PubMed     Abstract available
   
   
   
10. CONTEDUCA V, Scarpi E, Wetterskog D, Brighi N, et al
    Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients.
    Int J Cancer. 2022;150:1166-1173.
    PubMed     Abstract available
    
    
    March 2022
11. DIAZ DE LA GUARDIA-BOLIVAR E, Barrios-Rodriguez R, Zwir I, Jimenez-Moleon JJ, et al
    Identification of novel prostate cancer genes in patients stratified by Gleason classification: role of antitumoral genes.
    Int J Cancer. 2022 Mar 2. doi: 10.1002/ijc.33988.
    PubMed     Abstract available
    
    
    January 2022
12. ARSOV C, Albers P, Herkommer K, Gschwend J, et al
    A Randomized Trial of Risk-Adapted Screening for Prostate Cancer in Young Men - Results of the First Screening Round of the PROBASE Trial.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33940.
    PubMed    
    
    
    
13. FAN Z, Ma J, Pan X, Zhao L, et al
    Crosstalk of FGFR1 signaling and choline metabolism promotes cell proliferation and survival in prostate cancer cells.
    Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33922.
    PubMed     Abstract available
    
    
    December 2021
14. DJAMGOZ MBA
    Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33890.
    PubMed    
    
    
    
15. SALMINEN JK, Murtola TJ
    Reply to Comments on: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33887.
    PubMed    
    
    
    October 2021
16. PAYNE H, Robinson A, Rappe B, Hilman S, et al
    A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33845.
    PubMed     Abstract available
    
    
    
17. LI X, Cheng K, Li X, Zhou Y, et al
    Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
    Int J Cancer. 2021;149:1473-1482.
    PubMed     Abstract available
    
    
    September 2021
18. LIU D, Zhu J, Zhou D, Nikas EG, et al
    A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33808.
    PubMed     Abstract available
    
    
    July 2021
19. KOSTOS L, Hong W, Lee B, Tran B, et al
    Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
    Int J Cancer. 2021;149:409-419.
    PubMed     Abstract available
    
    
    April 2021
20. RASPIN K, FitzGerald LM, Marthick JR, Field MA, et al
    A rare variant in EZH2 is associated with prostate cancer risk.
    Int J Cancer. 2021 Apr 6. doi: 10.1002/ijc.33584.
    PubMed     Abstract available
    
    
    March 2021
21. HASAN MF, Ganapathy K, Sun J, Khatib A, et al
    LncRNA PAINT is Associated with Aggressive Prostate Cancer and Dysregulation of Cancer Hallmark Genes.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33569.
    PubMed     Abstract available
    
    
    February 2021
22. SALMINEN JK, Kuoppamaki V, Talala K, Taari K, et al
    Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33535.
    PubMed     Abstract available
    
    
    
23. FUJITA K, Hatano K, Tomiyama E, Hayashi Y, et al
    Serum core-type fucosylated PSA index for the detection of high-risk prostate cancer.
    Int J Cancer. 2021 Feb 16. doi: 10.1002/ijc.33517.
    PubMed     Abstract available
    
    
    
24. MONROY-IGLESIAS MJ, Russell B, Crawley D, Allen NE, et al
    Metabolic syndrome biomarkers and prostate cancer risk in the UK Biobank.
    Int J Cancer. 2021;148:825-834.
    PubMed     Abstract available
    
    
    
25. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    January 2021
26. XU F, Shangguan X, Pan J, Yue Z, et al
    HOXD13 Suppresses Prostate Cancer Metastasis and BMP4-induced EMT by Inhibiting SMAD1.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33494.
    PubMed     Abstract available
    
    
    November 2020
27. WATTS EL, Fensom GK, Smith Byrne K, Perez-Cornago A, et al
    Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in UK Biobank.
    Int J Cancer. 2020 Nov 30. doi: 10.1002/ijc.33416.
    PubMed     Abstract available
    
    
    
28. GEORGE G, Garmo H, Scailteux LM, Balusson F, et al
    Risk of cardiovascular disease following GnRH agonists versus antagonists in prostate cancer: Real-world evidence from five databases.
    Int J Cancer. 2020 Nov 13. doi: 10.1002/ijc.33397.
    PubMed     Abstract available
    
    
    
29. SUN X, Ye D, Du L, Qian Y, et al
    Genetically predicted levels of circulating cytokines and prostate cancer risk: A Mendelian randomization study.
    Int J Cancer. 2020;147:2469-2478.
    PubMed     Abstract available
    
    
    October 2020
30. MOLLER K, Kluth M, Ahmed M, Burkhardt L, et al
    Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.
    Int J Cancer. 2020 Oct 12. doi: 10.1002/ijc.33344.
    PubMed     Abstract available
    
    
    
31. HAO J, Ci X, Wang Y, Choi SYC, et al
    GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33335.
    PubMed     Abstract available
    
    
    
32. AKSOY O, Pencik J, Hartenbach M, Moazzami AA, et al
    Thyroid and androgen receptor signaling are antagonized by CRYM in prostate cancer.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33332.
    PubMed     Abstract available
    
    
    
33. WU J, Wei Y, Pan J, Jin S, et al
    Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33324.
    PubMed     Abstract available
    
    
    September 2020
34. WEITZER J, Castano-Vinyals G, Aragones N, Gomez-Acebo I, et al
    Effect of time of day of recreational and household physical activity on prostate and breast cancer risk (MCC-Spain Study).
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33310.
    PubMed     Abstract available
    
    
    
35. SLOOTBEEK PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, et al
    Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    Int J Cancer. 2020 Sep 23. doi: 10.1002/ijc.33306.
    PubMed     Abstract available
    
    
    
36. KARUNAMUNI RA, Huynh-Le MP, Fan CC, Thompson W, et al
    African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33282.
    PubMed     Abstract available
    
    
    
37. WOKOLORCZYK D, Kluzniak W, Huzarski T, Gronwald J, et al
    Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33272.
    PubMed     Abstract available
    
    
    August 2020
38. OUTZEN M, Tjonneland A, Hughes DJ, Jenab M, et al
    Toenail selenium, plasma selenoprotein P and risk of advanced prostate cancer: a nested case-control study.
    Int J Cancer. 2020 Aug 24. doi: 10.1002/ijc.33267.
    PubMed     Abstract available
    
    
    
39. BADRISING SK, Louhanepessy RD, van der Noort V, Coenen JLLM, et al
    A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
    Int J Cancer. 2020;147:1143-1151.
    PubMed     Abstract available
    
    
    July 2020
40. LUEBKE AM, Ricken W, Kluth M, Hube-Magg C, et al
    Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
    Int J Cancer. 2020;147:575-583.
    PubMed     Abstract available
    
    
    June 2020
41. JOCHEMS SHJ, Stattin P, Haggstrom C, Jarvholm B, et al
    Height, body mass index, and prostate cancer risk and mortality by way of detection and cancer risk category.
    Int J Cancer. 2020 Jun 11. doi: 10.1002/ijc.33150.
    PubMed     Abstract available
    
    
    
42. WENDEU-FOYET MG, Cenee S, Koudou Y, Tretarre B, et al
    Circadian genes polymorphisms, night work and prostate cancer risk: findings from the EPICAP study.
    Int J Cancer. 2020 Jun 7. doi: 10.1002/ijc.33139.
    PubMed     Abstract available
    
    
    May 2020
43. MORRISON GJ, Cunha AT, Jojo N, Xu Y, et al
    Cancer transcriptomic profiling from rapidly enriched circulating tumor cells.
    Int J Cancer. 2020;146:2845-2854.
    PubMed     Abstract available
    
    
    
44. MEYERS TJ, Weiner AB, Graff RE, Desai AS, et al
    Association between inflammatory bowel disease and prostate cancer: A large-scale, prospective, population-based study.
    Int J Cancer. 2020 May 13. doi: 10.1002/ijc.33048.
    PubMed     Abstract available
    
    
    
45. REMMERS S, Roobol MJ
    Personalized strategies in population screening for prostate cancer.
    Int J Cancer. 2020 May 11. doi: 10.1002/ijc.33045.
    PubMed     Abstract available
    
    
    
46. BORKOWETZ A, Froehner M, Rauner M, Conrad S, et al
    Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
    Int J Cancer. 2020;146:2619-2627.
    PubMed     Abstract available
    
    
    April 2020
47. HURWITZ LM, Yeboah ED, Biritwum RB, Tettey Y, et al
    Overall and abdominal obesity and prostate cancer risk in a West African population: an analysis of the Ghana Prostate Study.
    Int J Cancer. 2020 Apr 29. doi: 10.1002/ijc.33026.
    PubMed     Abstract available
    
    
    
48. NGUYEN-DUMONT T, MacInnis RJ, Steen JA, Theys D, et al
    Rare germline genetic variants and risk of aggressive prostate cancer.
    Int J Cancer. 2020 Apr 27. doi: 10.1002/ijc.33024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: